A prospective study of glycaemic status in anti-psychotic-treated patients

Journal of Psychopharmacology

Volumn 22, Issue 5, 2008, Pages 563-566

  Mackin, P ^a   Bishop, D ^a   Watkinson, H M ^a   Ferrier, I N ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anti psychotics; Bipolar disorder; Body mass index; Diabetes; Impaired fasting glucose; Schizophrenia

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; ARTICLE; BIPOLAR DISORDER; DIABETES MELLITUS; DRUG EFFECT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; UNITED KINGDOM; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; COHORT STUDIES; FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MENTAL DISORDERS; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 49349105409     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881107081532     Document Type: Article

References (14)

1. Colditz G.A., Willett W.C., Rotnitzky A. et al. (1995) Weight gain as a risk factor for clinical diabetes in women. Ann Inter Med 122: 481-486
2. Consensus development conference on antipsychotic drugs and obesity and diabetes (2004) Diabetes Care 27: 596-601
3. De Hert M., Hanssens L., van Winkel et al. (2006) Reversibility of antipsychotic treatment-related diabetes in patients with schizophrenia: a case series of switching to aripiprazole. Diabetes Care 29: 2329-2330
4. Holt R.I., Peveler R.C. (2006) Antipsychotic drugs and diabetes-an application of the Austin Bradford Hill criteria. Diabetologia 49: 1467-1476
5. Ko G.T., Chan J.C., Woo J. et al. (1998) Use of the 1997 American Diabetes association diagnostic criteria for diabetes in a Hong Kong Chinese population. Diabetes Care 21: 2094-2097
6. Lindenmayer J.P., Czobor P., Volavka J. et al. (2003) Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 160: 290-296
7. Lindström J., Louheranta A., Mannelin M. et al. (2003) The Finnish Diabetes Prevention Study (DPS). lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26: 3230-3236
8. Mackin P., Watkinson H.M., Young A.H. (2005) Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study. Diabetologia 48: 215-221
9. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057
10. Newcomer J.W., Haupt D.W. (2006) The metabolic effects of antipsychotic medications. Can J Psychiatry 51: 480-491
11. Peuskens H., De Hert M., Van Eyck D. et al. (2004) A case of reversible olanzapine-induced diabetes after switching to risperidone. Adv Schiz Clin Psych 1: 31-33
12. Tuomilehto J., Lindström J., Erikkson J.G., et al. (2001) Prevention of type 2 diabetes by changes in lifestyle among subjects with impaired glucose tolerance. NEJM 344: 1343-1350
13. Unwin N., Shaw J., Zimmet P. et al. (2002) Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 19: 708-723
14. de Vegt F., Dekker J.M., Stehouer C.D. et al. (2000) Similar 9-year mortality risks and reproducibility for the World Health Organisation and American Diabetes Association glucose tolerance categories: the Hoorn study. Diabetes Care 23: 40-44